Results 51 to 60 of about 762 (132)
The c‐Src inhibitor eCF506 diminishes opioid tolerance and reduces β‐arrestin2 recruitment
Morphine activation of μ receptors causes tolerance through c‐Src activation and β‐arrestin2 recruitment. c‐Src inhibition or degradation reduces β‐arrestin2 recruitment, μ receptor endocytosis, while causing receptor upregulation, all likely contributing to reduced morphine tolerance.
Samuel Singleton +6 more
wiley +1 more source
Introduction In the management of postoperative acute moderate-to-severe pain, opioids remain an important component. However, conventional opioids have a narrow therapeutic index and are associated with dose-limiting opioid-related ...
Wase, Linda +7 more
core +1 more source
Low Incidence of Opioid-Induced Respiratory Depression Observed with Oliceridine Regardless of Age or Body Mass Index: Exploratory Analysis from a Phase 3 Open-Label Trial in Postsurgical Pain [PDF]
IntroductionAdvanced age and obesity are reported to increase the risk of opioid-induced respiratory depression (OIRD). Oliceridine, an intravenous opioid, is a G-protein-biased agonist at the µ-opioid receptor that may provide improved safety.
Wase, Linda +9 more
core +1 more source
Spatiotemporal dynamics of β‐arrestin‐mediated Src activation in 5‐HT7 receptor signaling pathway
GPCRs induce distinct cellular responses via G protein‐ or β‐arrestin‐mediated signaling pathways. This study revealed that β‐arrestin‐biased 5‐HT7R ligand induces slow, sustained Src activation, contrasting with transient G protein‐mediated activation.
Hyunbin Kim +8 more
wiley +1 more source
Journey of Oliceridine: A Novel Opioid
Opioid analgesics play a crucial role in the management of acute pain, but its use is often limited by various adverse effects, especially nausea, vomiting, and respiratory depression.
A Tejus +3 more
doaj +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
Opioid drug binding to specialized G protein-coupled receptors (GPCRs) can lead to analgesia upon activation via downstream Gi protein signaling and to severe side effects via activation of the β-arrestin signaling pathway.
Hodošček, M. +11 more
core +1 more source
Novel Ligands for the Orphan Receptor GPR151 Modulate Morphine Action
The new GPR151 ligands altered the analgesic effects of morphine. ABSTRACT GPR151 is an orphan G‐protein‐coupled receptor expressed on specific neurons. Its expression has been reported to be upregulated in the dorsal root ganglia in mouse nerve injury models, suggesting a role in pain transmission.
Hijiri Yoshida +7 more
wiley +1 more source
Long‐term hearing loss with cognitive decline shows altered brain gradients, enlarged choroid plexus, and ventricles. These are linked to transcriptomic changes in synaptic, metabolic, and neurodegenerative pathways. ABSTRACT Long‐term sensorineural hearing loss (SNHL) is a prevalent condition associated with an increased risk of cognitive impairment ...
Xiao‐Min Xu +8 more
wiley +1 more source
Oliceridine for Analgesia in Elderly Patients Undergoing Kyphoplasty: From a Clinical Trial
Background As a G protein‐biased μ‐opioid receptor agonist, oliceridine can offer a relatively effective and safe analgesia. However, its effect on patients suffering from kyphoplasty was unexplored. Aim This study was aimed to determine the median effective dose (ED50) of oliceridine for analgesia during kyphoplasty in elderly patients across ...
Chenfang Miao +6 more
wiley +1 more source

